India mulls annual audit of raw material suppliers by drugmakers 

Central Drugs Standard Control Organisation said the annual audit proposed will replace the existing self inspection, quality audits and supplier audits

Updated - September 21, 2023 06:45 am IST - HYDERABAD

Representational image

Representational image | Photo Credit: AFP

India is considering making it mandatory for drugmakers to audit their raw material suppliers, atleast once a year.

Mooted by Central Drugs Standard Control Organisation at a meeting of drugmakers earlier this month on revised Schedule M (GMP), the proposal comes in the backdrop of World Health Organisation, beginning October 2022, flagging cough syrups made in India to death of several children in The Gambia and Uzbekistan.

In a presentation at the meeting, the regulator said the annual audit proposed will replace the existing self inspection, quality audits and supplier audits whose frequency is routine and on specific occasions such as product recall or inspection by the licencing authority (LA). The suppliers audit will cover raw material and packaging material.

Pointing out “all countries are looking at India for medicines” and compliance to good manufacturing practices (GMP) is mandatory, the regulator listed excipient compatibility and stability studies, quality culture at all levels, data integrity as well as multi product manufacturing facilities and loan licensing among the concerns and challenges.

Complying with GMP will help avoid mix-ups, contamination, cross contamination, errors while ensuring quality of drugs, patient safety and building trust and confidence, according to the presentation. Another key change proposed pertains to compliance and adverse reactions. As opposed to the existing practice of reporting to the LA only in the event of serious adverse drug reactions, the drugmakers would be required to report to the Authority faulty manufacture, product deterioration, serious quality problems. Under the proposed provision on product recall, the drugmakers will have inform the LA and comply with a comprehensive system specified for prompt and effective recall.

Though representatives of some drugmaker bodies are said to have expressed reservations in terms of the feasibility to conduct annual audit of raw material suppliers, the government is expected to shortly issue a notification or guidelines on the changes, sources said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.